📰 Thomask Equels News
Page 4 - Thomask Equels News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomask Equels. Real-time updates on events, politics, business and more.
August 8, 2023
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 -- AIM ImmunoTech Inc. today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
August 8, 2023
Topline data expected as early as Q1 2024...
July 10, 2023
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
July 5, 2023
OCALA, Fla., July 05, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
July 5, 2023
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ET...
June 14, 2023
Live webcast fireside chat on Wednesday, June 21st at 12:00 PM ETOCALA, Fla., June 14, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of... | June 14, 2023
June 12, 2023
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for... | June 12, 2023
May 15, 2023
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance... | May 15, 2023
May 11, 2023
AIM ImmunoTech Quarterly Stockholder Conference Call AIM ImmunoTech management will host a conference call and webcastto discuss the Companys Q1 2023 operational... | May 11, 2023
May 9, 2023
OCALA, Fla., May 09, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and... | May 9, 2023